Cause‐specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000–2016. (23rd February 2020)

• Record Type: Journal Article
• Authors: Dalal, Nicole H.; Dores, Graça M.; Curtis, Rochelle E.; Linet, Martha S.; Morton, Lindsay M.
• Is Part Of: British journal of haematology. Volume 189:Number 6(2020)
• Page Start: 1107
• Page End: 1118
• Publication Date: 2020-02-23
• Subjects: lymphoplasmacytic lymphoma -- Waldenström macroglobulinaemia -- cause‐specific mortality -- cancer epidemiology -- registry study -- standardised mortality ratio; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16492
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Data on cause‐specific mortality after lymphoplasmacytic lymphoma (LPL) and Waldenström macroglobulinaemia (WM) are lacking. We identified causes of death amongst 7289 adults diagnosed with incident first primary LPL ( n = 3108) or WM ( n = 4181) during 2000–2016 in 17 USA population‐based cancer registries. Based on 3132 deaths, 16‐year cumulative mortality was 23·2% for lymphomas, 8·4% for non‐lymphoma cancers and 14·7% for non‐cancer causes for patients aged <65 years at diagnosis of LPL/WM, versus 33·4%, 11·2% and 48·7%, respectively, for those aged ≥75 years. Compared with the general population, patients with LPL/WM had a 20% higher risk of death due to non‐cancer causes ( n = 1341 deaths, standardised mortality ratio [SMR] 1·2, 95% confidence interval [CI] 1·1–1·2), most commonly from infectious ( n = 188; SMR 1·8, 95% CI 1·6–2·1), respiratory ( n = 143; SMR 1·2, 95% CI 1·0–1·4), and digestive ( n = 80; SMR 1·8, 95% CI 1·4–2·2) diseases, but no excess mortality from cardiovascular diseases ( n = 477, SMR 1·1, 95% CI 1·0–1·1). Risks were highest for non‐cancer causes within 1 year of diagnosis ( n = 239; SMR<1year 1·3, 95% CI 1·2–1·5), declining thereafter ( n = 522; SMR≥5years 1·1, 95% CI 1·1–1·2). Myelodysplastic syndrome/acute myeloid leukaemia deaths were notably increased ( n = 46; SMR 4·4, 95% CI 3·2–5·9), whereas solid neoplasm deaths were only elevated among ≥5‐year survivors ( n = 145; SMR≥5years 1·3, 95% CI 1·1–1·5). This work identifies new areas for optimising care and reducing mortality for patients with LPL/WM.